2022CACLP Booth No.: A4-0501

In the first half of 2022, among the four major business lines of the company, the infectious disease business income reached 3.207 billion CNY, a significant increase of 240.32% over the same period of last year. Among them, the sales income of coronavirus detection reagents was about 3.020 billion CNY. The revenue of chronic disease management and detection was about 512 million CNY, which declined slightly due to the impact of epidemic prevention and control, but the chemiluminescence business achieved a breakthrough growth. The income from testing of eugenics and eugenics reached 127 million CNY, up 28.51% year-on-year. The revenue from drug abuse testing was 139 million CNY, an increase of 15.98% over the previous year.

In terms of infectious disease business, the covid-19 antigen business in Hong Kong and the mainland contributed more business growth in the first half of the year; The influenza epidemic intensity in the South increased, driving the recovery and growth of the company's influenza detection business. The company continues to take the four cards of infectious diseases as a breakthrough point to consolidate the second growth curve of domestic conventional infectious disease business. In the WHO` s public procurement market, the company has obtained PQ certification for self-test HIV products and EUL certification for coronavirus antigen testing products, laying a good foundation for the large-scale business in the public procurement market. In terms of chronic disease management business, in the first half of the year, the company continued to provide multi-dimensional and multi scenario solutions focusing on cardiovascular diseases, bleeding and coagulation diseases, respiratory emergencies and other critical diseases. In the first half of the year, affected by the domestic epidemic prevention and control, the overall business rhythm of the domestic hospital market fluctuated, but the chemiluminescence business increased significantly, and the sales of conventional projects and characteristic thrombus projects increased rapidly year on year.

In the international market, the sales of covid-19 related auxiliary diagnostic indicators declined. Other chronic disease management and testing projects in the international market still achieved rapid growth in the first half of this year. The company actively promotes the introduction of new platforms such as chemiluminescence and molecular diagnosis, carries out pilot promotion of new products and the establishment of new benchmark terminals according to the needs of the overseas testing market, radiates the surrounding countries, expands the overseas business scope, and expands the terminal scenarios such as hospital, pediatrics and pharmacy. Through the pilot, the company sets up new benchmarks, outputs promotion plans, forms a good brand promotion effect, and promotes the sustainable and stable development of overseas business. In recent years, Wondfo has continuously increased its investment in R & D and innovation. In the first half of 2022, the company invested 250 million CNY in R & D, a year-on-year increase of 17.14%, and completed the development of 79 new products.

Wondfo Bio's reserve of advanced technologies has also laid a solid foundation for the company's product landing, and made breakthroughs in several strategic areas. The company's single copy chemiluminescence immunoassay system was exhibited offline for the first time in China. The system combines the accuracy of chemiluminescence and the dexterity of POCT, and can meet the double requirements of grass-roots units for the accuracy of detection time and results. At present, the company has formed effective cooperation in tube lighting and single lighting products, further enhancing the product sequence and growth prospects in the chemiluminescence platform. In the field of molecular diagnosis, Wondfo Bio has rapidly entered the molecular track with its products related to coronavirus nucleic acid detection (virus sampling tube, nucleic acid extraction reagent, extractor and PCR instrument). In the first half of this year, the company's self-developed U-box automatic nucleic acid amplification and analysis system was successfully approved. The system can automatically realize the whole experimental process of nucleic acid extraction, amplification and analysis. The results can be automatically issued and printed within one hour. It can be widely used in the detection of pathogens, tumor related gene mutations and drug resistance gene mutations. In the field of pathology business, Wondfo biological pathology business model has gradually entered the landing stage from the exploration stage. Pa3600, a full-automatic immunohistochemical staining machine with independent intellectual property rights, has been put into trial use in many benchmark terminals across the country, laying a solid foundation for steady reagent sales next year. At present, the in vitro diagnosis industry is in a rapid development stage. Wondfo biological will carry out strategic layout and business development "based on China and facing the world", drive the continuous and rapid growth of performance through the expansion of endogenous business, and introduce technology and channel layout through extensive M & A, so as to achieve sustainable business combination and leading advantages, continuously improve operating efficiency and consolidate the competitiveness of the company in the in vitro diagnosis industry.